TY - JOUR AU - Faissner, S. AU - Gold, R. PY - 2018 DA - 2018// TI - Efficacy and safety of the newer multiple sclerosis drugs approved since 2010 JO - CNS Drugs VL - 32 UR - https://doi.org/10.1007/s40263-018-0488-6 DO - 10.1007/s40263-018-0488-6 ID - Faissner2018 ER - TY - JOUR AU - Zhang, X. AU - Tao, Y. AU - Chopra, M. PY - 2013 DA - 2013// TI - Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis JO - J Immunol VL - 191 UR - https://doi.org/10.4049/jimmunol.1301926 DO - 10.4049/jimmunol.1301926 ID - Zhang2013 ER - TY - STD TI - European Medical Agency. Lemtrada summary of products characteristics. https://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003718/human_med_001678.jsp&mid=WC0b01ac058001d124. Accessed 19 Mar 2019. UR - https://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003718/human_med_001678.jsp&mid=WC0b01ac058001d124 ID - ref3 ER - TY - JOUR AU - Canham, L. J. W. AU - Manara, A. AU - Fawcett, J. PY - 2018 DA - 2018// TI - Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis JO - Mult Scler Relat Disord VL - 24 UR - https://doi.org/10.1016/j.msard.2018.05.014 DO - 10.1016/j.msard.2018.05.014 ID - Canham2018 ER - TY - JOUR AU - Holmoy, T. AU - Lippe, H. AU - Leegaard, T. M. PY - 2017 DA - 2017// TI - Listeria monocytogenes infection associated with alemtuzumab—a case for better preventive strategies JO - BMC Neurol VL - 17 UR - https://doi.org/10.1186/s12883-017-0848-8 DO - 10.1186/s12883-017-0848-8 ID - Holmoy2017 ER - TY - JOUR AU - Myro, A. Z. AU - Bjerke, G. AU - Zarnovicky, S. AU - Holmoy, T. PY - 2018 DA - 2018// TI - Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report JO - BMC Pharmacol Toxicol VL - 19 UR - https://doi.org/10.1186/s40360-018-0267-5 DO - 10.1186/s40360-018-0267-5 ID - Myro2018 ER - TY - JOUR AU - Yiannopoulou, K. G. AU - Papadimitriou, D. AU - Anastasiou, A. I. AU - Siakantaris, M. PY - 2018 DA - 2018// TI - Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion JO - Mult Scler Relat Disord VL - 23 UR - https://doi.org/10.1016/j.msard.2018.04.014 DO - 10.1016/j.msard.2018.04.014 ID - Yiannopoulou2018 ER - TY - JOUR AU - Metz, I. AU - Rieckmann, P. AU - Kallmann, B. A. AU - Bruck, W. PY - 2016 DA - 2016// TI - Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis JO - Acta Neuropathol Commun VL - 4 UR - https://doi.org/10.1186/s40478-016-0352-1 DO - 10.1186/s40478-016-0352-1 ID - Metz2016 ER - TY - JOUR AU - Saarela, M. AU - Senthil, K. AU - Jones, J. PY - 2018 DA - 2018// TI - Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab JO - Neurology VL - 90 UR - https://doi.org/10.1212/WNL.0000000000005420 DO - 10.1212/WNL.0000000000005420 ID - Saarela2018 ER - TY - STD TI - US Food and Drug Administration 2005. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. https://www.fda.gov/files/drugs/published/Good-Pharmacovigilance-Practices-and-Pharmacoepidemiologic-Assessment-March-2005.pdf. Accessed 15 May 2019. UR - https://www.fda.gov/files/drugs/published/Good-Pharmacovigilance-Practices-and-Pharmacoepidemiologic-Assessment-March-2005.pdf ID - ref10 ER - TY - STD TI - The Uppsala Monitoring Centre. The Use of the WHO-UMC system for standardised casse causality assesment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed 21 Mar 2019. UR - https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf ID - ref11 ER - TY - JOUR AU - Croteau, D. AU - Flowers, C. AU - Kulick, C. G. AU - Brinker, A. AU - Kortepeter, C. M. PY - 2018 DA - 2018// TI - Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab JO - Neurology VL - 90 UR - https://doi.org/10.1212/WNL.0000000000005422 DO - 10.1212/WNL.0000000000005422 ID - Croteau2018 ER - TY - STD TI - US Food and Drug Administration 2018. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab). Safety Announc. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf. Accessed 14 Mar 2019. UR - https://www.fda.gov/downloads/Drugs/DrugSafety/UCM626584.pdf ID - ref13 ER - TY - JOUR AU - Azevedo, C. J. AU - Kutz, C. AU - Dix, A. AU - Boster, A. AU - Sanossian, N. AU - Kaplan, J. PY - 2019 DA - 2019// TI - Intracerebral haemorrhage during alemtuzumab administration JO - Lancet Neurol VL - 18 UR - https://doi.org/10.1016/S1474-4422(19)30076-6 DO - 10.1016/S1474-4422(19)30076-6 ID - Azevedo2019 ER - TY - JOUR AU - Baker, D. AU - Giovannoni, G. AU - Schmierer, K. PY - 2017 DA - 2017// TI - Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment JO - Mult Scler Relat Disord VL - 18 UR - https://doi.org/10.1016/j.msard.2017.09.028 DO - 10.1016/j.msard.2017.09.028 ID - Baker2017 ER - TY - JOUR AU - Rieckmann, P. AU - Lenz, A. AU - Hoffmann, M. AU - Poske, U. AU - Behr, K. AU - Kallmann, B. PY - 2016 DA - 2016// TI - Fatal autoimmune hemolytic anemia associated with alemtuzumab in a MS patient with severe relapsing remitting disease course and prior immune therapies JO - Neurology VL - 86 ID - Rieckmann2016 ER - TY - STD TI - Bundesärztekammer. Arzneimittelkommission der Deutschen Ârzteschaft. Theraprefraktäre Autoimmunthrombozytopenie nach Alemtuzumab zur Behandlung einer Multiplen Sklerose. Deutsche Arzteblatt 2017;114:A2175–6. ID - ref17 ER - TY - JOUR AU - Baker, D. AU - Herrod, S. S. AU - Alvarez-Gonzalez, C. AU - Giovannoni, G. AU - Schmierer, K. PY - 2017 DA - 2017// TI - Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab JO - JAMA Neurol VL - 74 UR - https://doi.org/10.1001/jamaneurol.2017.0676 DO - 10.1001/jamaneurol.2017.0676 ID - Baker2017 ER - TY - JOUR AU - Thomas, K. AU - Eisele, J. AU - Rodriguez-Leal, F. A. AU - Hainke, U. AU - Ziemssen, T. PY - 2016 DA - 2016// TI - Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS JO - Neurol Neuroimmunol Neuroinflam VL - 3 UR - https://doi.org/10.1212/NXI.0000000000000228 DO - 10.1212/NXI.0000000000000228 ID - Thomas2016 ER - TY - JOUR AU - Wing, M. G. AU - Moreau, T. AU - Greenwood, J. PY - 1996 DA - 1996// TI - Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells JO - J Clin Invest VL - 98 UR - https://doi.org/10.1172/JCI119110 DO - 10.1172/JCI119110 ID - Wing1996 ER - TY - JOUR AU - Cuker, A. AU - Bass, A. D. AU - Nadj, C. PY - 2019 DA - 2019// TI - Immune thrombocytopenia in alemtuzumab-treated MS patients: incidence, detection, and management JO - Mult Scler UR - https://doi.org/10.1177/1352458518816612 DO - 10.1177/1352458518816612 ID - Cuker2019 ER - TY - JOUR AU - Goldman, S. A. PY - 1998 DA - 1998// TI - Limitations and strengths of spontaneous reports data JO - Clin Therap VL - 20 UR - https://doi.org/10.1016/S0149-2918(98)80007-6 DO - 10.1016/S0149-2918(98)80007-6 ID - Goldman1998 ER - TY - STD TI - Coles A, Robertson N, Al-Araji A et al. Association of British neurologist 2017. Guidance on the prevention of Listeria infection after alemtuzumab treatment of multiple sclerosis. https://www.theabn.org/news/new-guidelines-on-the-prevention-of-listeria-infection.html. Accessed 15 May 2019. UR - https://www.theabn.org/news/new-guidelines-on-the-prevention-of-listeria-infection.html ID - ref23 ER -